# Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

> **NCT04353765** · — · COMPLETED · sponsor: **Ipsen** · enrollment: 247 (actual)

## Conditions studied

- Locally Advanced or Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib monotherapy
- **DRUG:** All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC

## Key facts

- **NCT ID:** NCT04353765
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-30
- **Primary completion:** 2020-06-05
- **Final completion:** 2020-06-05
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2021-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353765, "Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04353765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*